Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Accuray Incorporated (NASDAQ: ARAY) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including annual reports, quarterly reports and current reports on Form 8-K. As a radiation oncology company that develops and manufactures systems such as the CyberKnife and Radixact platforms, Accuray uses its SEC filings to report on financial performance, capital structure, governance decisions and material corporate events that matter to ARAY shareholders and analysts.
In its periodic reports, such as the Form 10-K and Form 10-Q, Accuray presents audited and unaudited financial statements, segment information, discussions of product and service revenue, gross profit, operating expenses, net income or loss, cash and debt balances, and non-GAAP measures like adjusted EBITDA. These filings also contain risk factor disclosures and management’s discussion and analysis, which address topics such as macroeconomic conditions, supply chain dynamics, tariffs, international operations and joint venture arrangements.
Current reports on Form 8-K provide more immediate insight into specific developments. Recent 8-K filings describe amendments to a financing agreement with TCW Asset Management Company LLC, including changes to liquidity calculations, delayed draw term loan conditions and covenant timing, as well as the issuance of warrants to purchase shares of common stock with defined exercise prices, terms and anti-dilution provisions. Other 8-Ks cover restructuring actions under a strategic, operational and organizational transformation plan, including workforce reductions and estimated restructuring charges, and governance matters such as equity incentive plan approvals, director elections, executive transitions and consulting arrangements.
Proxy materials, including the definitive proxy statement on Form DEF 14A, outline proposals submitted to stockholders, such as director elections, approval of the 2026 Equity Incentive Plan, advisory votes on executive compensation and ratification of the independent registered public accounting firm. These documents also describe corporate governance practices, board structure and executive compensation programs.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Real-time updates from the SEC’s EDGAR system ensure that new 10-K, 10-Q and 8-K reports, as well as proxy statements and other relevant forms, are available as they are filed. For those tracking insider-related information, Form 4 and other ownership filings can be reviewed alongside financial and governance disclosures to build a more complete picture of Accuray’s regulatory and corporate history.
Accuray Incorporated (ARAY) disclosed a director equity grant. On 10/31/2025, a director acquired 354,609 shares of common stock classified as restricted shares under the Accuray Incorporated Amended and Restated 2016 Equity Incentive Plan.
The shares were recorded at a transaction price of $0 and are held directly. Following the transaction, the director beneficially owned 354,609 common shares. The award vests 100% on the first anniversary of the grant date.
Accuray Incorporated (ARAY) filed a Form S-8 to register shares of common stock for issuance under two stand-alone equity award agreements: an Inducement Restricted Stock Unit Agreement and an Inducement Performance Unit Agreement. These agreements are intended to grant equity awards outside of the company’s existing stock plans.
The filing incorporates by reference Accuray’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, specified Current Reports on Form 8-K, and the description of its common stock on Form 8-A. It also details standard Delaware law and company bylaw provisions for indemnification of directors and officers, along with related opinion and consent exhibits.
Aevum Pension Fund reports beneficial ownership of 5,473,256 shares of Accuray Inc. common stock, representing 4.86% of the outstanding class. The filing states the shares are held by a pension fund organized in Switzerland and that Aevum has sole voting and dispositive power over the reported shares. The statement certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Accuray Incorporated requests stockholder approval of director elections and a new 2026 Equity Incentive Plan while describing fiscal 2025 compensation outcomes and governance practices. The company reported fiscal 2025 revenue of $459 million (87% of the bonus-plan target), orders net of cancellations of $288 million (97% of target), and adjusted EBITDA of $28.8 million (65% of target), and the Compensation Committee determined not to pay cash incentive awards for fiscal 2025.
The proxy lists three Class I director nominees and Board recommendations to vote FOR the nominees, the 2026 Plan, and the advisory approval of named executive officer compensation. Key equity metrics disclosed include three-year equity grants totaling ~15.06 million shares (FY2023–FY2025), an average three-year burn rate of 3.89%, an overhang of 11% at fiscal year-end, and 4,815,031 shares available for issuance under the 2016 Plan as of June 30, 2025 (increased ~295,000 by terminations).
Accuray Incorporated entered into a consulting agreement with its Senior Vice President, Chief Legal Officer and Corporate Secretary, Jesse Chew, in connection with his departure on September 19, 2025. The agreement covers transition and consulting services from September 19, 2025 through December 31, 2025.
For these services, Mr. Chew will receive a $20,000 monthly retainer and continued vesting of his outstanding Accuray equity awards during the consulting term. The full consulting agreement is included as an exhibit to the report.
Anne Bryce Le Grand, a director of Accuray Incorporated (ARAY), reported receipt of 78,947 restricted stock units (RSUs) on 08/29/2025. Each RSU represents a contingent right to one share of the issuer's common stock and the award vests 100% on 08/29/2026, resulting in 78,947 shares beneficially owned following the transaction. The filing was signed by Jesse Chew as Power of Attorney for Anne Bryce Le Grand on 09/03/2025. No cash price was paid for the RSUs as reported.
Accuray Incorporated reported upcoming leadership and board changes. On August 19, 2025, director Robert C. Kill, a Class I director, informed the Board that he will not stand for re-election at the company’s 2025 annual meeting of stockholders scheduled for November 2025. He will continue serving on the Board and its Compensation Committee until that meeting concludes, and the company states his decision is not due to any disagreement with the company, the Board, or its operations, policies, or practices.
Also on August 19, 2025, Jesse Chew notified the company of his intent to resign as Senior Vice President, Chief Legal Officer and Corporate Secretary, effective September 19, 2025. He has agreed to consult with Accuray through December 31, 2025 under terms to be determined. The company notes that his resignation is likewise not the result of any disagreement with the company or the Board.
Accuray Inc. (ARAY) has received an amended Schedule 13G filing (Amendment No. 5) from Neuberger Berman Group LLC and Neuberger Berman Investment Advisers LLC. As of 07/31/2025 the Neuberger entities beneficially own 5,242,373 common shares, equal to 4.65 % of Accuray’s outstanding stock. The institutions report shared voting power over 3,991,789 shares and shared dispositive power over the full 5,242,373 shares; they hold no sole voting or dispositive authority. Because the position now falls below the 5 % threshold, Item 5 (“ownership of 5 % or less”) is checked. The filing is made under Rule 13d-1(b), classifying the filers as a parent holding company (HC) and an investment adviser (IA). The signatory, Managing Director Brad Cetron, certifies that the shares were acquired in the ordinary course of business and not to influence control of Accuray.